Tandem Diabetes Care (NASDAQ:TNDM) Earns Daily Media Impact Rating of 0.14

News coverage about Tandem Diabetes Care (NASDAQ:TNDM) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the medical device company an impact score of 45.7460044537285 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Tandem Diabetes Care (NASDAQ:TNDM) opened at $3.24 on Friday. Tandem Diabetes Care has a fifty-two week low of $2.15 and a fifty-two week high of $30.00. The company has a market capitalization of $33.90, a price-to-earnings ratio of -0.16 and a beta of 0.17. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, October 26th. The medical device company reported ($3.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($3.74) by $0.65. The company had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.92 million. During the same quarter in the prior year, the business posted ($0.97) earnings per share. The company’s revenue was up 119.7% compared to the same quarter last year. equities analysts predict that Tandem Diabetes Care will post -15.37 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Saturday, January 6th. Wedbush reiterated an “outperform” rating and issued a $17.00 price target (down from $50.00) on shares of Tandem Diabetes Care in a report on Tuesday, October 10th. Piper Jaffray Companies reiterated a “hold” rating and issued a $15.00 price target on shares of Tandem Diabetes Care in a report on Friday, October 6th. Finally, Robert W. Baird restated a “hold” rating and set a $3.00 price objective on shares of Tandem Diabetes Care in a report on Sunday, November 19th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Tandem Diabetes Care has a consensus rating of “Hold” and a consensus target price of $11.29.

ILLEGAL ACTIVITY WARNING: “Tandem Diabetes Care (NASDAQ:TNDM) Earns Daily Media Impact Rating of 0.14” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-tandem-diabetes-care-tndm-share-price.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply